Arch Biopartners Inc V.ARCH

Arch Biopartners - My Due Diligence

[Riverfolk]

Here is the science published by a world renounced third party:

Dipeptidase-1 ( Metablok)


mice, with survival increasing from 0% to 83%

Here is the technology developer and CSO explaining Metablok on a webinar:

Metablok Webinar

Here is the link for the Method of use Patent:

Metablok Patent

https://www.archbiopartners.com/index.php/investor-hub/fundamentals/press-releases-live/154-arch-biopartners-discloses-new-patent-filing-for-novel-drug-candidates-to-prevent-lung-inflammation

https://www.archbiopartners.com/index.php/investor-hub/fundamentals/press-releases-live/32-press-releases-2019/144-arch-biopartners-announces-issuance-of-us-patent-for-dipeptidase-1-inhibitor-drug-for-use-in-acute-kidney-injury

Here is the market potential for the kidney alone:

Currently, no specific therapies exist to prevent AKI in the world today. Management of AKI is supportive and includes life-sustaining therapy with dialysis. Patients that experience AKI are at high risk of developing chronic kidney disease, adverse cardiovascular outcomes and death.The worldwide market for AKI is estimated to be over $20 billion USD per year. ($325.4 dollars a share)

Currently the market cap is 153 million US

Acute Kidney Injury

Here is the scientific community endorsement:

The Government of Canada Funded Arch for the Phase II trial after recommendations of the countries top scientists.

https://bc.ctvnews.ca/video?clipId=2101344

Prime Minister Of Canada Announcement - Arch Biopartners

The CIHR grant entitled “Therapeutic Targeting a Shared Inflammation Pathway in the Lungs and Kidneys” was awarded

Here is the expanding of the Phase II trial in Canada, Turkey and The USA:

Turkish Ministry Of Health

Health Canada Protocol

Additional Canadian Hospital

Here is the final dosing with 65 patients enrolled:

65 enrolled , 61 dosed

Here is the Clinical Trials Link:

https://clinicaltrials.gov/ct2/show/NCT04402957

Here is the link to Sedar:

No warrants outstanding

The Company had 47,360,179 Common Shares outstanding as of May 7, 2010. As of the date hereinabove, the Company has 61,862,302 common shares outstanding.

Arch Biopartners Historic Bought Financings

 

Dec 23, 2020 (One Placee)

announced it has closed the non-brokered private placement the Company disclosed in a press release December 23, 2020 (The “Offering”). Pursuant to the Offering, Arch issued 430,000 common shares priced at CAD $1.50 per common share (the “Common Shares”) for net proceeds of $500,000 USD (approximately $645,000 CAD) (the “Offering”).

June 30, 2020 (Two Placee)

The Company announced it closed a non-brokered private placement offering of 900,000 common shares priced at $1.50 per common share (the “Common Shares”) for gross and net proceeds of up to $1,350,000 (the “Offering”).

Feb 2, 2018 (One Placee)

The Company announced it arranged a non-brokered private placement offering of up to 2,500,000 common shares priced at $0.50 per common share (the “Common Shares”) for gross proceeds of up to $1,250,000 (the “Offering”).